JP Morgan Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $146

Benzinga Newsdesk www.benzinga.com Positive 75.4%

Neg 0% Neu 0% Pos 75.4%

JP Morgan analyst Priyanka Grover maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $145 to $146.